The latest update is out from Terns Pharmaceuticals ( (TERN) ).
Terns Pharmaceuticals, Inc. reported promising results from a Phase 1 trial of its once-daily oral GLP-1R agonist, TERN-601, showing significant and dose-dependent weight loss in obese or overweight healthy adults. With no serious adverse events and good tolerability even at high doses, the drug is poised for Phase 2 trials in 2025. The findings suggest TERN-601 could be an effective monotherapy or part of a combination treatment for obesity, marking a potential breakthrough for weight management therapies.
For a thorough assessment of TERN stock, go to TipRanks’ Stock Analysis page.
